arginine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1549	74-79-3

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: l-arginine L-Arg arginine arginine hydrochloride arginine HCl	An essential amino acid that is physiologically active in the L-form. Molecular weight: 174.20 Formula: C6H14N4O2 CLOGP: -3.04 LIPINSKI: 0 HAC: 6 HDO: 5 TPSA: 125.22 ALOGS: -1.88 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

l-arginine
L-Arg
arginine
arginine hydrochloride
arginine HCl

An essential amino acid that is physiologically active in the L-form.

Molecular weight: 174.20
Formula: C6H14N4O2
CLOGP: -3.04
LIPINSKI: 0
HAC: 6
HDO: 5
TPSA: 125.22
ALOGS: -1.88
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	68 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.32 L/kg	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

Date	Agency	Company
June 23, 2021	PMDA	FUJIFILM TOYAMA CHEMICAL Co., Ltd.
Feb. 28, 1973	FDA	PHARMACIA AND UPJOHN
July 25, 2019	EMA	Advanced Accelerator Applications

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperammonaemic crisis	58.76	24.94	7	945	32	63488038
Foetal growth restriction	58.52	24.94	15	937	7538	63480532
Infantile apnoea	42.03	24.94	8	944	1025	63487045
Selective eating disorder	36.47	24.94	8	944	2064	63486006
Hyperammonaemia	33.80	24.94	9	943	5223	63482847
Cerebral haemorrhage	30.96	24.94	13	939	30716	63457354
Ammonia increased	30.03	24.94	8	944	4648	63483422
Right ventricular failure	26.89	24.94	10	942	17178	63470892
Device related sepsis	26.24	24.94	7	945	4087	63483983

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperammonaemic crisis	84.48	25.13	11	1032	52	34955836
Haematuria	77.43	25.13	35	1008	50031	34905857
Blindness cortical	57.55	25.13	10	1033	383	34955505

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperammonaemic crisis	108.45	21.65	14	1653	93	79742628
Haematuria	72.12	21.65	33	1634	68803	79673918
Blindness cortical	51.89	21.65	10	1657	977	79741744
Hyperammonaemia	39.63	21.65	13	1654	11080	79731641
Ammonia increased	35.76	21.65	11	1656	7624	79735097
Blood osmolarity decreased	26.28	21.65	6	1661	1325	79741396
Status epilepticus	26.15	21.65	12	1655	25029	79717692

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B05XB01	BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS I.V. SOLUTION ADDITIVES Amino acids
ATC	V03AF11	VARIOUS ALL OTHER THERAPEUTIC PRODUCTS ALL OTHER THERAPEUTIC PRODUCTS Detoxifying agents for antineoplastic treatment
CHEBI has role	CHEBI:27027	trace elements
CHEBI has role	CHEBI:50733	Dietary Supplement
CHEBI has role	CHEBI:59163	biological marker
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:76971	Escherichia coli metabolites
CHEBI has role	CHEBI:78675	fundamental metabolites
CHEBI has role	CHEBI:75772	S. cerevisiae metabolites
CHEBI has role	CHEBI:77746	Homo sapiens metabolite

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Renal radiation exposure from Lutetium (177Lu) oxodotreotide	indication	218190002
Diagnostic Test for Growth Hormone Secretion	indication
Renal tubular acidosis	contraindication	1776003	DOID:14219
Classical phenylketonuria	contraindication	7573000
Poisoning by digitalis glycoside	contraindication	12876009
Hyperkalemia	contraindication	14140009
Constipation	contraindication	14760008	DOID:2089
Sarcoidosis	contraindication	31541009	DOID:11335
Dehydration	contraindication	34095006
End stage renal disease	contraindication	46177005	DOID:784
Humoral hypercalcemia of malignancy	contraindication	47709007
Heart disease	contraindication	56265001	DOID:114
Metabolic acidosis	contraindication	59455009
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Ventricular fibrillation	contraindication	71908006
Hypercalciuria	contraindication	71938000
Kidney disease	contraindication	90708001	DOID:557
Kidney stone	contraindication	95570007
Hb SS disease	contraindication	127040003	DOID:10923
Osteolysis	contraindication	203522001
Myocardial infarction in recovery phase	contraindication	418044006
Allergic Reactions	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	1.97	acidic
pKa2	11.72	Basic
pKa3	8.95	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Nitric oxide synthase, inducible	Enzyme	P35228	NOS2_HUMAN		Kd	5.15		CHEMBL
G-protein coupled receptor family C group 6 member A	GPCR	Q5T6X5	GPC6A_HUMAN	AGONIST	EC50	4.40		IUPHAR

External reference:

ID	Source
4018668	VUID
N0000146979	NUI
D02982	KEGG_DRUG
1119-34-2	SECONDARY_CAS_RN
4018668	VANDF
4019067	VANDF
C0003765	UMLSCUI
CHEBI:29016	CHEBI
ARG	PDB_CHEM_ID
CHEMBL1485	ChEMBL_ID
CHEMBL1200381	ChEMBL_ID
D001120	MESH_DESCRIPTOR_UI
DB00125	DRUGBANK_ID
721	IUPHAR_LIGAND_ID
1711	INN_ID
94ZLA3W45F	UNII
6322	PUBCHEM_CID
DB17289	DRUGBANK_ID
1091	RXNORM
14778	MMSL
206	MMSL
40033	MMSL
4219	MMSL
7609	MMSL
7610	MMSL
d00578	MMSL
000926	NDDF
005095	NDDF
52625008	SNOMEDCT_US
63676001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
R-Gene	HUMAN PRESCRIPTION DRUG LABEL	1	0009-0436	INJECTION, SOLUTION	10 g	INTRAVENOUS	NDA	17 sections
R-Gene	HUMAN PRESCRIPTION DRUG LABEL	1	0009-0436	INJECTION, SOLUTION	10 g	INTRAVENOUS	NDA	17 sections
R-Gene	HUMAN PRESCRIPTION DRUG LABEL	1	0009-0436	INJECTION, SOLUTION	10 g	INTRAVENOUS	NDA	17 sections
ProcalAmine	HUMAN PRESCRIPTION DRUG LABEL	22	0264-1915	INJECTION	0.29 g	INTRAVENOUS	NDA	24 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-1933	SOLUTION	1.20 g	INTRAVENOUS	NDA	23 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-1933	SOLUTION	1.20 g	INTRAVENOUS	NDA	23 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-1933	SOLUTION	1.20 g	INTRAVENOUS	NDA	23 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-3200	SOLUTION	1.47 g	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-3205	SOLUTION	1.47 g	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-4500	SOLUTION	1.47 g	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-4500	SOLUTION	1.47 g	INTRAVENOUS	ANDA	20 sections
Plenamine	HUMAN PRESCRIPTION DRUG LABEL	17	0264-4500	SOLUTION	1.47 g	INTRAVENOUS	ANDA	20 sections
FreAmine III	HUMAN PRESCRIPTION DRUG LABEL	16	0264-9010	INJECTION, SOLUTION	0.95 g	INTRAVENOUS	NDA	24 sections
FreAmine III	HUMAN PRESCRIPTION DRUG LABEL	16	0264-9011	INJECTION, SOLUTION	0.95 g	INTRAVENOUS	NDA	24 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-9341	SOLUTION	1.20 g	INTRAVENOUS	NDA	23 sections
TrophAmine	HUMAN PRESCRIPTION DRUG LABEL	20	0264-9361	SOLUTION	0.73 g	INTRAVENOUS	NDA	23 sections
HepatAmine	HUMAN PRESCRIPTION DRUG LABEL	16	0264-9371	INJECTION, SOLUTION	0.60 g	INTRAVENOUS	NDA	23 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0180	INJECTION	920 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0180	INJECTION	920 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0184	INJECTION, EMULSION	920 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0184	INJECTION, EMULSION	920 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0188	INJECTION	920 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0188	INJECTION	920 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0194	INJECTION	920 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0194	INJECTION	920 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0198	INJECTION	690 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX	HUMAN PRESCRIPTION DRUG LABEL	16	0338-0198	INJECTION	690 mg	INTRAVENOUS	NDA	21 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	920 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	920 mg	INTRAVENOUS	NDA	20 sections
CLINIMIX E	HUMAN PRESCRIPTION DRUG LABEL	21	0338-0202	INJECTION	920 mg	INTRAVENOUS	NDA	20 sections